Mr. Ajay Mishra reports

NUGEN ANNOUNCES FILING OF CORRECTIVE DISCLOSURE PURSUANT TO OSC REVIEW

Nugen Medical Devices Inc., further to the review by the Ontario Securities Commission (OSC) of the company's continuous disclosure, has made corrective disclosure with respect to the following:

• The company has included in its recently filed management information circular dated Aug. 17, 2026, the executive compensation disclosure for the year ended Dec. 31, 2025, required pursuant to National Instrument 51-102, Continuous Disclosure Obligations.
• The company has included in the circular the corporate governance disclosure required pursuant to form NI 58-102F2, Corporate Governance Disclosure (Venture Issuers), and the audit committee disclosure required pursuant to Form 52-110F2, Disclosure by Venture Issuers.

The circular has been filed on the company's SEDAR+ profile.

Corrective disclosure was requested by OSC staff in connection with the company's continuous disclosure. The company has provided explanations to OSC staff requests and has also included the requested information in the circular.

As a result of having to provide such corrective disclosure, the company will be placed on the public list of refilling and errors in accordance with OSC Staff Notice 51-711 and will remain on the list for a period of three years from the date of refiling the corrective disclosure.

About Nugen Medical Devices Inc.

Nugen develops needle-free devices for subcutaneous drug delivery. Its flagship InsuJet system is approved in 42 countries and is designed to improve the lives of millions of people with diabetes worldwide.

We seek Safe Harbor.